Market open
MoonLake Immunotherapeutics/$MLTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
Ticker
$MLTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Zug, Switzerland
Employees
100
Website
MLTX Metrics
BasicAdvanced
$2.4B
-
-$1.89
1.30
-
Price and volume
Market cap
$2.4B
Beta
1.3
52-week high
$58.26
52-week low
$36.52
Average daily volume
324K
Financial strength
Current ratio
21.113
Quick ratio
20.071
Long term debt to equity
0.321
Total debt to equity
0.624
Management effectiveness
Return on assets (TTM)
-17.81%
Return on equity (TTM)
-25.08%
Valuation
Price to book
5.33
Price to tangible book (TTM)
5.33
Price to free cash flow (TTM)
-20.261
Growth
Earnings per share change (TTM)
158.08%
3-year earnings per share growth (CAGR)
-38.69%
MLTX News
AllArticlesVideos
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
GlobeNewsWire·2 weeks ago
MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon
Seeking Alpha·2 months ago
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for MoonLake Immunotherapeutics stock?
MoonLake Immunotherapeutics (MLTX) has a market cap of $2.4B as of March 12, 2025.
What is the P/E ratio for MoonLake Immunotherapeutics stock?
The price to earnings (P/E) ratio for MoonLake Immunotherapeutics (MLTX) stock is 0 as of March 12, 2025.
Does MoonLake Immunotherapeutics stock pay dividends?
No, MoonLake Immunotherapeutics (MLTX) stock does not pay dividends to its shareholders as of March 12, 2025.
When is the next MoonLake Immunotherapeutics dividend payment date?
MoonLake Immunotherapeutics (MLTX) stock does not pay dividends to its shareholders.
What is the beta indicator for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics (MLTX) has a beta rating of 1.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.